| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.073 |
| Chemical and physical data | |
| Formula | C16H18N4O2 |
| Molar mass | 298.346 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nialamide (Niamid,Niamide,Nuredal,Surgex) is a non-selective,irreversiblemonoamine oxidase inhibitor (MAOI) of thehydrazine class that was used as anantidepressant.[2] It was withdrawn byPfizer several decades ago due to the risk ofhepatotoxicity.[3][4]
Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarelyleukopenia and hepatitis. As with other MAOIs, ahypertensive crisis can be triggered by co-ingestion oftyramine. It is metabolized intoisoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.[5]
The antiatherogenic activity of nialamide was used to designpyridinolcarbamate.[6]